Anti-NGF antibody slow-release microspheres for reducing airway hyperreactivity and preparation method thereof

A technology of airway hyperresponsiveness and slow-release microspheres, which is applied in the direction of antibodies, antibody medical ingredients, and medical preparations of non-active ingredients, etc., can solve the problem of no anti-NGF antibody drugs, etc., to reduce airway hyperresponsiveness , reduce airway inflammation, does not affect the effect of systemic immune function

Inactive Publication Date: 2021-09-07
AFFILIATED HOSPITAL OF GUILIN MEDICAL UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Asthma is a chronic bronchial airway inflammatory disease, and there are no related reports on the preparation method of anti-NGF antibody drugs in inhibiting bronchial airway hyperresponsiveness

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-NGF antibody slow-release microspheres for reducing airway hyperreactivity and preparation method thereof
  • Anti-NGF antibody slow-release microspheres for reducing airway hyperreactivity and preparation method thereof
  • Anti-NGF antibody slow-release microspheres for reducing airway hyperreactivity and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] 1. Anti-NGF antibody micronization

[0035] The concentration of the bovine serum albumin solution configured is 0.5mg / mL, the concentration of the anti-NGF antibody solution is 2mL / kg, 300 μg of the anti-NGF antibody solution is mixed with 0.5 ml of bovine serum albumin solution, and then lyophilized, and then freeze-dried Conditions are freezing at -20°C for 3 hours; drying at 20°C for 12 hours. After the mixture was lyophilized, it was uniformly dispersed in the bovine serum albumin matrix to form anti-NGF antibody powder.

[0036] 2. Anti-NGF microencapsulation

[0037] S1: Mix polylactic acid and glycolic acid in a weight ratio of 1:2 to prepare polylactic acid;

[0038] S2: Mix 10 mg of NGF antibody micropowder with 300 mg of polylactic acid, dissolve in 1 mL of dichloromethane to form an oil phase;

[0039] S3: Prepare 8 mL of 2% polyvinyl alcohol solution, add it to the oil phase, and stir at high speed for 20 seconds to form an S / O / W type double emulsion;

...

Embodiment 2

[0043] 1. Anti-NGF antibody micronization

[0044]The concentration of the bovine serum albumin solution configured is 0.6mg / mL, the concentration of the anti-NGF antibody solution is 4mL / kg, 300 μg of the anti-NGF antibody solution is mixed with 0.5 ml of bovine serum albumin solution, and then lyophilized, and then freeze-dried Conditions were freezing at -30°C for 3 hours; drying at 20°C for 12 hours. After the mixture was lyophilized, it was uniformly dispersed in the bovine serum albumin matrix to form anti-NGF antibody powder.

[0045] 2. Anti-NGF microencapsulation

[0046] S1: Mix polylactic acid and glycolic acid in a weight ratio of 1:5 to prepare polylactic acid;

[0047] S2: Mix 20mg of NGF antibody micropowder with 300mg of polylactic acid, dissolve in 3mL of dichloromethane to form an oil phase;

[0048] S3: Prepare 15 mL of 2% polyvinyl alcohol solution, add it to the oil phase, and stir at high speed for 60 seconds to form an S / O / W type double emulsion;

[...

Embodiment 3

[0051] 1. Anti-NGF antibody micronization

[0052] The concentration of the bovine serum albumin solution configured is 0.8mg / mL, the concentration of the anti-NGF antibody solution is 6mL / kg, 300 μg of the anti-NGF antibody solution is mixed with 0.5 ml of bovine serum albumin solution, and then lyophilized. Conditions are freezing at -20°C for 3 hours; drying at 20°C for 12 hours. After the mixture was lyophilized, it was uniformly dispersed in the bovine serum albumin matrix to form anti-NGF antibody powder.

[0053] 2. Anti-NGF microencapsulation

[0054] S1: Mix polylactic acid and glycolic acid in a weight ratio of 1:3 to prepare polylactic acid;

[0055] S2: Mix 12mg of NGF antibody micropowder with 300mg of polylactic acid, dissolve in 2mL of dichloromethane to form an oil phase;

[0056] S3: Prepare 10 mL of 2% polyvinyl alcohol solution, add it to the oil phase, and stir at high speed for 30 seconds to form an S / O / W type double emulsion;

[0057] S4: Prepare 10% ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
concentrationaaaaaaaaaa
encapsulation rateaaaaaaaaaa
Login to view more

Abstract

The invention discloses an anti-NGF antibody slow-release microsphere for reducing airway hyperresponsiveness and a preparation method thereof. The anti-NGF antibody drug is prepared as a slow-release microsphere, which is used for treating asthma by atomizing inhalation. Airway hyperresponsiveness. For the first time, this application uses nebulized inhalation of anti-NGF antibody microspheres to reduce airway inflammation and airway hyperresponsiveness, delay or even reverse the progression of asthma; nebulized inhalation of anti-NGF antibody slow-release microspheres can reduce airway damage, It does not affect or even promote the effect of airway repair; unlike the systemic anti-NGF inhibition strategy, the anti-NGF sustained-release microspheres are guided to the damaged nerve endings exposed in the asthmatic airway mucosa and subendothelium by means of atomized microspheres It has the advantages of strong targeting, high efficiency, safety, and does not affect the host's systemic immune function. The combined treatment of aerosol inhalation and anti-NGF microspheres has more advantages.

Description

technical field [0001] The invention relates to the field of medicine preparation, in particular to anti-NGF antibody slow-release microspheres for reducing airway hyperreactivity and a preparation method. Background technique [0002] Nerve growth factor (NGF) is a neuropeptide that plays a nutritional role in the growth and differentiation of nerve cells. It is composed of α, β, γ three kinds of peptide chains, a covalently bonded multimer formed in the proportion of α2βγ2, and two zinc ester structures. Asthma is a chronic bronchial airway inflammatory disease, and there is no relevant report on the preparation method of anti-NGF antibody drugs in inhibiting bronchial airway hyperresponsiveness. [0003] The disclosure of the above background technical content is only used to assist in understanding the inventive concepts and technical solutions of the present invention, and it does not necessarily belong to the prior art of this application. If there is no clear evidenc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K9/72A61K9/52A61K39/395A61K47/34A61K47/32A61P11/06
CPCA61K9/007A61K9/5026A61K9/5031A61K39/3955A61P11/06
Inventor 佘巍巍梅正敏周治德
Owner AFFILIATED HOSPITAL OF GUILIN MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap